Premium
Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12‐core biopsy results
Author(s) -
Wysock James S.,
Mendhiratta Neil,
Zattoni Fabio,
Meng Xiaosong,
Bjurlin Marc,
Huang William C.,
Lepor Herbert,
Rosenkrantz Andrew B.,
Taneja Samir S.
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13427
Subject(s) - magnetic resonance imaging , prostate biopsy , prostate , core (optical fiber) , predictive value , core biopsy , medicine , nuclear magnetic resonance , value (mathematics) , biopsy , radiology , nuclear medicine , physics , optics , mathematics , statistics , cancer , breast cancer
Objectives To evaluate the cancer detection rates for men undergoing 12‐core systematic prostate biopsy with negative prebiopsy multiparametric magnetic resonance imaging (mp MRI ) results. Materials and Methods Clinical data from consecutive men undergoing prostate biopsy who had undergone prebiopsy 3T mp MRI from December 2011 to August 2014 were reviewed from an institutional review board‐approved prospective database. Men with negative prebiospy mp MRI results (neg MRI ) before biopsy were identified for the present analysis. Clinical features, cancer detection rates and negative predictive values were summarized. Results Seventy five men with neg MRI underwent systematic 12‐core biopsy during the study period. In the entire cohort, men with no previous biopsy, men with previously negative biopsy and men enrolled in active surveillance protocols, the overall cancer detection rates were 18.7, 13.8, 8.0 and 38.1%, respectively, and the detection rates for Gleason score ( GS ) ≥7 cancer were 1.3, 0, 4.0 and 0%, respectively. The NPV s for all cancers were 81.3, 86.2, 92.0, and 61.9, and for GS ≥7 cancer they were 98.7, 100, 96.0 and 100%, respectively. Conclusions A negative prebiopsy mp MRI confers an overall NPV of 82% on 12‐core biopsy for all cancer and 98% for GS ≥7 cancer. Based on biopsy indication, these findings assist in prebiopsy risk stratification for detection of high‐risk disease and may provide guidance in the decision to pursue biopsy.